Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
作者信息
Yilmaz Musa, Alfayez Mansour, DiNardo Courtney D, Borthakur Gautam, Kadia Tapan M, Konopleva Marina Y, Loghavi Sanam, Kanagal-Shamanna Rashmi, Patel Keyur P, Jabbour Elias J, Garcia-Manero Guillermo, Pemmaraju Naveen, Pierce Sherry A, Ghayas Issa, Short Nicholas J, Montalban-Bravo Guillermo, Takahashi Koichi, Assi Rita, Alotaibi Ahmad S, Ohanian Maro, Andreeff Michael, Cortes Jorge E, Kantarjian Hagop M, Ravandi Farhad, Daver Naval G
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Hematol Oncol. 2021 Feb 23;14(1):34. doi: 10.1186/s13045-020-01023-9.
Abstract
摘要
相似文献
1
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.对《急性髓系白血病患者基于序贯FLT3抑制剂治疗的结果》的更正
J Hematol Oncol. 2021 Feb 23;14(1):34. doi: 10.1186/s13045-020-01023-9.
2
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.伴有 FLT3 抑制剂的序贯治疗在 AML 患者中的疗效。
J Hematol Oncol. 2020 Oct 8;13(1):132. doi: 10.1186/s13045-020-00964-5.
3
Emergence of - Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series.基于FLT3抑制剂治疗的急性髓系白血病中-融合的出现：一种潜在的可靶向耐药机制——病例系列
Front Oncol. 2020 Oct 20;10:588876. doi: 10.3389/fonc.2020.588876. eCollection 2020.
4
FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.在FLT3-ITD突变型急性髓系白血病的临床前模型中，奥雷巴替尼（HQP1351）抑制FLT3可下调MCL-1，并与BCL-2抑制剂利沙妥昔（APG-2575）协同作用。
Transl Oncol. 2022 Jan;15(1):101244. doi: 10.1016/j.tranon.2021.101244. Epub 2021 Oct 25.
5
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.口服 HDAC 抑制剂 pracinostat（SB939）与 JAK2 抑制剂 pacritinib（SB1518）在 AML 的临床前模型中具有疗效和协同作用。
Blood Cancer J. 2012 May;2(5):e69. doi: 10.1038/bcj.2012.14. Epub 2012 May 4.
6
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.第二代FLT3抑制剂治疗复发/难治性急性髓系白血病患者的系统评价
Leuk Res. 2024 Jun;141:107505. doi: 10.1016/j.leukres.2024.107505. Epub 2024 Apr 17.
7
[Current status and challenges of AML treatment with FLT3 inhibitors].[FLT3抑制剂治疗急性髓系白血病的现状与挑战]
Rinsho Ketsueki. 2024;65(7):684-692. doi: 10.11406/rinketsu.65.684.
8
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.通过STAT5失活抑制BCL2A1可克服FLT3-ITD/D835突变型急性髓系白血病对靶向治疗的耐药性。
Transl Oncol. 2022 Apr;18:101354. doi: 10.1016/j.tranon.2022.101354. Epub 2022 Feb 1.
9
Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.两名对维奈克拉加阿扎胞苷无反应的FLT3-ITD突变急性髓系白血病患者对基于吉瑞替尼和维奈克拉的治疗产生快速有效反应
Onco Targets Ther. 2022 Feb 18;15:159-164. doi: 10.2147/OTT.S336715. eCollection 2022.
10
Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.Wu-5，一种新型的 USP10 抑制剂，通过抑制 FLT3 和 AMPK 通路增强 crenolanib 诱导的 FLT3-ITD 阳性 AML 细胞死亡。
Acta Pharmacol Sin. 2021 Apr;42(4):604-612. doi: 10.1038/s41401-020-0455-x. Epub 2020 Jul 21.
引用本文的文献
1
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.急性髓系白血病中FLT3的治疗靶点：现状与新方法
Onco Targets Ther. 2022 Nov 30;15:1449-1478. doi: 10.2147/OTT.S384293. eCollection 2022.
2
Which FLT3 Inhibitor for Treatment of AML?哪种FLT3抑制剂可用于治疗急性髓系白血病？
Curr Treat Options Oncol. 2022 Mar;23(3):359-380. doi: 10.1007/s11864-022-00952-6. Epub 2022 Mar 8.
本文引用的文献
1
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.伴有 FLT3 抑制剂的序贯治疗在 AML 患者中的疗效。
J Hematol Oncol. 2020 Oct 8;13(1):132. doi: 10.1186/s13045-020-00964-5.
2
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
3
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Quizartinib 与挽救性化疗治疗复发或难治性 FLT3-ITD 急性髓系白血病（QuANTUM-R）：一项多中心、随机、对照、开放标签、3 期临床试验。
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
4
Targeting FLT3 mutations in AML: review of current knowledge and evidence.AML 中 FLT3 突变的靶向治疗：现有知识和证据的综述。
Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16.
5
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.2b 期单药quizartinib 治疗 ITD 突变的复发/难治性 AML 的 2 种剂量方案研究。
Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.
6
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.Quizartinib，一种 FLT3 抑制剂，作为复发或难治性急性髓系白血病患者的单药治疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
7
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.吉瑞替尼对复发或难治性急性髓系白血病中FLT3的选择性抑制作用：一项多中心、首例人体、开放标签的1-2期研究。
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
8
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
9
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
10
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.索拉非尼联合标准疗法与安慰剂联合标准疗法治疗 60 岁及以下初诊急性髓系白血病患者（SORAML）：一项多中心、2 期、随机对照试验。
Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.
Zotero 插件